Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Receivables: 2020-2025

Historic Receivables for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $60.9 million.

  • GeneDx Holdings' Receivables rose 59.44% to $60.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.6 million, marking a year-over-year increase of 55.00%. This contributed to the annual value of $37.6 million for FY2024, which is 16.24% up from last year.
  • Per GeneDx Holdings' latest filing, its Receivables stood at $60.9 million for Q3 2025, which was up 26.88% from $48.0 million recorded in Q2 2025.
  • GeneDx Holdings' Receivables' 5-year high stood at $60.9 million during Q3 2025, with a 5-year trough of $21.7 million in Q3 2021.
  • Over the past 3 years, GeneDx Holdings' median Receivables value was $35.8 million (recorded in 2023), while the average stood at $38.2 million.
  • As far as peak fluctuations go, GeneDx Holdings' Receivables spiked by 116.59% in 2022, and later tumbled by 32.02% in 2023.
  • GeneDx Holdings' Receivables (Quarterly) stood at $26.6 million in 2021, then skyrocketed by 66.15% to $44.1 million in 2022, then fell by 26.65% to $32.4 million in 2023, then grew by 16.24% to $37.6 million in 2024, then skyrocketed by 59.44% to $60.9 million in 2025.
  • Its Receivables stands at $60.9 million for Q3 2025, versus $48.0 million for Q2 2025 and $46.0 million for Q1 2025.